Live Analyst Rating Changes 25399 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jay Olson
OPCO

Jay Olson

Oppenheimer
Wall Street Analyst
★★★★☆
#576
on 13Foresight · ranked by our own returns
59%
Success Rate
+13.2%
Average Return
51 of 86 calls profitable · +64.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 59% of Jay Olson's ratings turned a profit when each position was held for 1 year — averaging +13.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

116 Buy 19 Hold 0 Sell
Jay's Stock Coverage 65 ratings · 2026-08-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ATAI
Atai Beckley N.V.
 Aug 17, 2026 HOLD Buy
+24.9% avg upside
17 analysts
 — · ·
PRAX
Praxis Precision Medicines
 Aug 17, 2026 BUY Strong Buy
+48.0% avg upside
24 analysts
$650.00
72.73% Upside
 · ·
BIIB
Biogen
 Aug 17, 2026 HOLD Strong Buy
+20.8% avg upside
52 analysts
 — · ·
KYNB
Kyntra Bio
 Aug 14, 2026 BUY Buy
+356.6% avg upside
15 analysts
$35.00
413.94% Upside
 · ·
APRE
Aprea Therapeutics
 Aug 13, 2026 BUY Buy
+3216.7% avg upside
7 analysts
$5.00
624.71% Upside
 +1.3% ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Aug 12, 2026 BUY Strong Buy
+134.8% avg upside
9 analysts
$23.58
148.26% Upside
 +2.4% ·
SGMT
Sagimet Biosciences, Inc. Class A
 Aug 12, 2026 BUY Strong Buy
+168.5% avg upside
15 analysts
$33.00
216.33% Upside
 +12.3% ·
DFTX
Definium Therapeutics
 Aug 07, 2026 BUY Strong Buy
+15.2% avg upside
22 analysts
$60.00
32.52% Upside
 -7.6% ·
QTTB
Q32 Bio
 Aug 06, 2026 BUY Buy
+276.0% avg upside
24 analysts
$40.00
150.78% Upside
 -6.5% ·
BIOA
BioAge Labs, Inc.
 Aug 06, 2026 BUY Strong Buy
+240.5% avg upside
9 analysts
$50.00
380.82% Upside
 -5.9% ·
RVMD
Revolution Medicines
 Aug 06, 2026 BUY Strong Buy
-20.1% avg upside
32 analysts
$230.00
8.51% Upside
 +8.4% ·
CHRS
Coherus Biosciences
 Aug 06, 2026 BUY Buy
+972.2% avg upside
18 analysts
$10.00
769.47% Upside
 -4.8% ·
AMGN
Amgen
 Aug 05, 2026 BUY Buy
-24.2% avg upside
57 analysts
$450.00
7.32% Upside
 +1.8% ·
FTH
Faeth Therapeutics
 Aug 05, 2026 BUY Strong Buy
+35.1% avg upside
16 analysts
$60.00
83.17% Upside
 +31.5% ·
VKTX
Viking Therapeutics
 Aug 03, 2026 BUY Strong Buy
+114.1% avg upside
31 analysts
$100.00
197.27% Upside
 +1.8% ·
NBIX
Neurocrine
 Jul 31, 2026 BUY Strong Buy
+21.6% avg upside
37 analysts
$230.00
48.94% Upside
 -8.4% ·
INCY
Incyte
 Jul 28, 2026 BUY Buy
-11.8% avg upside
47 analysts
$120.00
2.78% Downside
 -5.0% ·
INO
Inovio Pharmaceuticals
 Jul 20, 2026 HOLD Buy
+680.7% avg upside
19 analysts
 — +0.0% ·
SKYE
Skye Bioscience
 Jul 20, 2026 HOLD Buy
+2272.6% avg upside
9 analysts
 — -23.2% ·
VRTX
Vertex Pharmaceuticals
 Jul 20, 2026 HOLD Strong Buy
-13.5% avg upside
62 analysts
 — +5.2% ·
CMPS
COMPASS Pathways
 Jul 07, 2026 BUY Strong Buy
+62.2% avg upside
20 analysts
$20.00
45.69% Upside
 +3.5% ·
ZNTL
Zentalis Pharmaceuticals
 Jun 15, 2026 BUY Buy
+278.6% avg upside
18 analysts
$9.00
143.00% Upside
 -5.8% ·
ANL
Adlai Nortye Ltd. Sponsored ADR
 May 28, 2026 BUY Strong Buy
+61.2% avg upside
7 analysts
$32.00
139.78% Upside
 +17.3% ·
TVRD
Tvardi Therapeutics
 May 11, 2026 BUY Strong Buy
+840.8% avg upside
23 analysts
$10.00
437.71% Upside
 -52.0% ·
DNLI
Denali Therapeutics
 May 11, 2026 BUY Strong Buy
+57.8% avg upside
24 analysts
$40.00
64.22% Upside
 +24.1% ·
NKTR
Nektar Therapeutics
 May 08, 2026 BUY Strong Buy
+3.0% avg upside
26 analysts
$140.00
92.73% Upside
 -10.8% ·
EXEL
Exelixis
 Apr 27, 2026 HOLD Buy
-17.0% avg upside
34 analysts
 — +14.8% ·
PASG
Passage Bio
 Apr 27, 2026 HOLD Buy
+284.0% avg upside
14 analysts
 — -19.6% ·
BNTX
BioNTech SE
 Apr 27, 2026 HOLD Strong Buy
+45.7% avg upside
26 analysts
 — -8.8% ·
HRMY
Harmony Biosciences Holdings
 Apr 22, 2026 BUY Strong Buy
+27.3% avg upside
13 analysts
$72.00
88.69% Upside
 +19.2% ·
MRNA
Moderna
 Apr 20, 2026 HOLD Hold
+10.5% avg upside
38 analysts
 — +16.0% ·
BCYC
Bicycle Therapeutics
 Mar 18, 2026 BUY Strong Buy
+506.1% avg upside
21 analysts
$36.00
800.09% Upside
 -17.0% ·
IMRX
Immuneering
 Mar 09, 2026 BUY Strong Buy
+249.6% avg upside
12 analysts
$30.00
474.62% Upside
 -10.0% ·
MDGL
Madrigal Pharmaceuticals
 Feb 09, 2026 BUY Strong Buy
-3.5% avg upside
33 analysts
$650.00
23.91% Upside
 +4.0% ·
OVID
Ovid Therapeutics
 Nov 13, 2025 BUY Strong Buy
+75.7% avg upside
18 analysts
$7.00
142.30% Upside
 +135.8% ·
IBIO
Ibio
 Nov 13, 2025 BUY Strong Buy
+302.3% avg upside
11 analysts
$6.00
313.84% Upside
 +24.3% ·
NTLA
Intellia Therapeutics
 Nov 07, 2025 BUY Buy
+221.2% avg upside
37 analysts
$27.00
123.28% Upside
 +25.1% ·
IONS
Ionis Pharmaceuticals
 Oct 27, 2025 BUY Strong Buy
+35.5% avg upside
43 analysts
$90.00
53.57% Upside
 -21.6% ·
GANX
Gain Therapeutics
 Oct 07, 2025 BUY Strong Buy
+282.4% avg upside
9 analysts
$8.00
292.06% Upside
 +5.0% ·
VYGR
Voyager Therapeutics
 Oct 02, 2025 BUY Strong Buy
+342.2% avg upside
23 analysts
$18.00
457.27% Upside
 -30.7% ·
PRTA
Prothena
 Jun 16, 2025 HOLD Buy
+181.4% avg upside
14 analysts
 — +46.5% ·
JSPR
Jasper Therapeutics
 Jun 16, 2025 BUY Buy
+3441.6% avg upside
18 analysts
$65.00
7617.88% Upside
 -92.0% ·
STRO
Sutro Biopharma
 Mar 14, 2025 HOLD Strong Buy
+91.4% avg upside
21 analysts
 — +184.9% ·
GILD
Gilead Sciences
 Feb 12, 2025 BUY Strong Buy
-14.3% avg upside
66 analysts
$115.00
17.27% Downside
 +51.0% ·
ENTA
Enanta Pharmaceuticals
 Dec 10, 2024 HOLD Buy
+154.4% avg upside
17 analysts
$14.00
9.05% Upside
 +66.3% ·
ACAD
ACADIA Pharmaceuticals
 Nov 08, 2024 HOLD Strong Buy
+27.2% avg upside
43 analysts
$17.00
41.39% Downside
 +27.8% ·
CRSP
Crispr Therapeutics AG
 Nov 06, 2024 BUY Buy
+40.2% avg upside
41 analysts
$95.00
74.98% Upside
 +11.6% ·
EDIT
Editas Medicine
 Nov 05, 2024 HOLD Buy
+383.7% avg upside
33 analysts
 — -10.9% ·
CGTX
Cognition Therapeutics
 Nov 04, 2024 BUY Strong Buy
+477.6% avg upside
9 analysts
$9.00
782.43% Upside
 +231.2% ·
DMRA
Damora Therapeutics
 Oct 17, 2024 BUY Strong Buy
-7.1% avg upside
20 analysts
$10.00
67.76% Downside
 +42.4% ·
BIVI
BioVie
 Feb 26, 2024 HOLD Buy
+1220.0% avg upside
6 analysts
 — · ·
KRRO
Korro Bio
 Feb 14, 2023 HOLD Strong Buy
+106.5% avg upside
19 analysts
 — +46.7% ·
RLMD
Relmada Therapeutics
 Nov 14, 2022 BUY Strong Buy
+190.1% avg upside
15 analysts
$7.00
46.66% Upside
 -52.3% ·
KURA
Kura Oncology
 Aug 14, 2020 HOLD Strong Buy
+129.2% avg upside
26 analysts
 — -21.4% ·
TPST
Tempest Therapeutics
 Jun 12, 2020 HOLD Buy
+1884.6% avg upside
18 analysts
 — · ·
IMVIF
IMV
 May 08, 2020 HOLD Hold
+154378136.0% avg upside
7 analysts
 — · ·
TXMD
TherapeuticsMD
 Aug 22, 2019 BUY Hold
+210.5% avg upside
8 analysts
$9.00
347.85% Upside
 · ·
MDWD
Mediwound
 Aug 14, 2019 BUY Strong Buy
+59.3% avg upside
13 analysts
$7.00
47.75% Downside
 +16.9% ·
INDP
Indaptus Therapeutics
 Jul 22, 2019 HOLD Buy
+9162.0% avg upside
6 analysts
 — · ·
SPRO
Spero Therapeutics
 Mar 24, 2019 BUY Buy
+1052.5% avg upside
12 analysts
 — -49.8% ·
VTGN
VistaGen Therapeutics
 Mar 15, 2019 HOLD Hold
+879.6% avg upside
8 analysts
 — · ·
TARA
Protara Therapeutics
 Dec 08, 2017 HOLD Strong Buy
+1195.1% avg upside
21 analysts
 — -7.9% ·
ARCT
Arcturus Therapeutics
 Jan 20, 2017 HOLD Buy
+260.9% avg upside
36 analysts
 — +32.0% ·
TNXP
Tonix Pharma
 Dec 30, 2016 HOLD Strong Buy
+119.5% avg upside
8 analysts
 — · ·
MNKD
MannKind
 Mar 30, 2016 SELL Buy
+80.6% avg upside
22 analysts
$0.25
93.68% Downside
 +82.3% ·
🔒 60 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jay Olson — Frequently Asked Questions
How accurate are Jay Olson's stock ratings?
Based on the calls 13Foresight could measure, about 59% of Jay's ratings were profitable over a one-year hold, with an average return of +13.2% per rating, or +64.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jay ranked on 13Foresight?
Jay Olson is currently ranked #576 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jay cover?
Jay most recently has ratings on ATAI, PRAX, BIIB, KYNB, APRE, TSE:EPRX, SGMT, DFTX, QTTB, BIOA, RVMD, CHRS and 53 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.